Cherri Sewell, APRN
Nurse Practitioner · South Point, OHNPI 1407287923
Payments from drug & device makers
Across 281 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$941
- AstraZeneca$780
- Pfizer$505
- Boehringer Ingelheim$502
- Lilly USA, LLC$452
- Sanofi-aventis U.S. LLC$162
- plus $945 from 17 others
What the payments were for
- Food & beverage$4,285100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $941 |
| AstraZeneca | 40 | $780 |
| Pfizer | 37 | $505 |
| Boehringer Ingelheim | 29 | $502 |
| Lilly USA, LLC | 33 | $452 |
| Sanofi-aventis U.S. LLC | 11 | $162 |
| Mylan Specialty L.p. | 9 | $143 |
| Biohaven Pharmaceuticals, Inc. | 9 | $136 |
| Amgen | 7 | $116 |
| Novo Nordisk | 6 | $106 |
| Bayer | 5 | $99 |
| Abbott | 5 | $86 |
| Dexcom, Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Verona Pharma, Inc. | 1 | $28 |
| Exact Sciences | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| GSK | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$4,286 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $189,448 |
| TrulicityDulaglutide | 122 | $123,502 |
| JardianceEmpagliflozin | 99 | $115,488 |
| MounjaroTirzepatide | 69 | $87,099 |
| FarxigaDapagliflozin Propanediol | 98 | $79,674 |
| EliquisApixaban | 79 | $77,913 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $38,011 |
| VraylarCariprazine Hcl | 23 | $32,969 |
| Advair HfaFluticasone Propion/Salmeterol | 63 | $28,318 |
| Nurtec OdtRimegepant Sulfate | 14 | $28,229 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $25,951 |
| LinzessLinaclotide | 28 | $23,860 |
| JanuviaSitagliptin Phosphate | 23 | $22,679 |
| XareltoRivaroxaban | 18 | $18,731 |
| VascepaIcosapent Ethyl | 41 | $16,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $452 | $210,601191 claims |
| Novo NordiskOzempic | $106 | $189,44886 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $502 | $131,291122 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $780 | $111,793145 claims |
| PfizerEliquis, Nurtec Odt | $505 | $106,14393 claims |
| AbbVieVraylar, Linzess, Synthroid | $941 | $58,38781 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $49,27971 claims |
| MerckJanuvia | $12 | $22,67923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in South Point
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.